Ruxolitinib as an Emerging Treatment in Myelofibrosis

Blood and Lymphatic Cancer: Targets and Therapy

doi 10.2147/blctt.s24926

Full Text

Abstract

Available in

Date

March 1, 2013

Authors

Publisher

Informa UK Limited

Related search

Definition and Management of Ruxolitinib Treatment Failure in Myelofibrosis

Blood Cancer Journal

English

Efficacy of Ruxolitinib for Myelofibrosis

Expert Opinion on Pharmacotherapy

English

Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects

Clinical Lymphoma, Myeloma and Leukemia

Cancer Research

English

Cost-Effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain

Journal of Health Economics and Outcomes Research

English

Safety and Efficacy of Ruxolitinib in Myelofibrosis Patients Without Splenomegaly

British Journal of Haematology

English

Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I

Clinical Lymphoma, Myeloma and Leukemia

Cancer Research

English

Emerging Drugs for Myelofibrosis

Expert Opinion on Emerging Drugs

English

JAK Inhibition With Ruxolitinib Versus Best Available Therapy for Myelofibrosis

New England Journal of Medicine

English

Primary Myelofibrosis Associated Glomerulopathy: Significant Improvement After Therapy With Ruxolitinib

English